|
EED expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.87103674168065E-13 |
| Normal-vs-Stage2 |
1.25579990850611E-10 |
| Normal-vs-Stage3 |
5.75095526755831E-14 |
| Normal-vs-Stage4 |
1.79078973872038E-12 |
| Stage1-vs-Stage2 |
4.386100E-02 |
| Stage1-vs-Stage3 |
2.187600E-02 |
| Stage1-vs-Stage4 |
5.057500E-03 |
| Stage2-vs-Stage3 |
7.783200E-01 |
| Stage2-vs-Stage4 |
6.120000E-01 |
| Stage3-vs-Stage4 |
3.641400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
3.72739999976446E-08 |
| Normal-vs-Asian |
1.044700E-04 |
| Caucasian-vs-AfricanAmerican |
5.942400E-01 |
| Caucasian-vs-Asian |
5.859400E-03 |
| AfricanAmerican-vs-Asian |
3.054300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
1.63125069008174E-12 |
| Male-vs-Female |
9.106500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.48479015141356E-12 |
| Normal-vs-Age(41-60Yrs) |
1.04360964314765E-14 |
| Normal-vs-Age(61-80Yrs) |
1.87116988570324E-12 |
| Normal-vs-Age(81-100Yrs) |
1.77348000000022E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.747420E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.640030E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.383210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.944600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.298400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.748800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.171600E-02 |
| Classical-VS-Follicular |
2.349600E-02 |
| Classical-VS-Other |
5.554400E-01 |
| Classical-VS-Normal |
1.74682490694522E-12 |
| Tall-VS-Follicular |
5.916200E-01 |
| Tall-VS-Other |
6.341800E-01 |
| Tall-VS-Normal |
8.53830339764272E-11 |
| Follicular-VS-Other |
8.725600E-01 |
| Follicular-VS-Normal |
2.33790764525565E-12 |
| Other-VS-Normal |
8.640500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.35447209004269E-13 |
| Normal-vs-N1 |
6.41670050427479E-11 |
| N0-vs-N1 |
5.800800E-01 |
|
|
